Concepts (232)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Bone Neoplasms | 24 | 2023 | 118 | 5.640 |
Why?
|
| Sarcoma | 14 | 2023 | 140 | 2.320 |
Why?
|
| Bone Substitutes | 7 | 2017 | 8 | 1.890 |
Why?
|
| Soft Tissue Neoplasms | 7 | 2022 | 52 | 1.670 |
Why?
|
| Giant Cell Tumor of Bone | 5 | 2022 | 16 | 1.500 |
Why?
|
| Bone Transplantation | 7 | 2017 | 155 | 1.440 |
Why?
|
| Calcium Sulfate | 4 | 2012 | 6 | 0.920 |
Why?
|
| Limb Salvage | 5 | 2023 | 12 | 0.850 |
Why?
|
| Hip Joint | 2 | 2016 | 242 | 0.820 |
Why?
|
| Neoplasm Recurrence, Local | 7 | 2023 | 202 | 0.770 |
Why?
|
| Humans | 48 | 2023 | 22932 | 0.760 |
Why?
|
| Adult | 21 | 2022 | 6931 | 0.720 |
Why?
|
| Retrospective Studies | 24 | 2023 | 2995 | 0.710 |
Why?
|
| Young Adult | 12 | 2021 | 1653 | 0.700 |
Why?
|
| Adolescent | 15 | 2021 | 1882 | 0.690 |
Why?
|
| Leiomyosarcoma | 1 | 2021 | 23 | 0.670 |
Why?
|
| Child | 12 | 2021 | 1157 | 0.660 |
Why?
|
| Calcium Phosphates | 2 | 2012 | 16 | 0.640 |
Why?
|
| Fractures, Bone | 2 | 2012 | 70 | 0.610 |
Why?
|
| Bone Cysts | 2 | 2016 | 2 | 0.600 |
Why?
|
| Tibia | 2 | 2010 | 197 | 0.590 |
Why?
|
| Male | 24 | 2021 | 12460 | 0.560 |
Why?
|
| Child, Preschool | 8 | 2021 | 567 | 0.560 |
Why?
|
| Treatment Outcome | 14 | 2023 | 2941 | 0.550 |
Why?
|
| Middle Aged | 19 | 2021 | 7915 | 0.540 |
Why?
|
| Arthroplasty, Replacement, Knee | 5 | 2022 | 560 | 0.530 |
Why?
|
| Chondromatosis, Synovial | 1 | 2016 | 4 | 0.510 |
Why?
|
| Sarcoma, Ewing | 1 | 2016 | 5 | 0.500 |
Why?
|
| Bone Diseases | 2 | 2017 | 19 | 0.500 |
Why?
|
| Female | 20 | 2021 | 12958 | 0.500 |
Why?
|
| Arthrodesis | 2 | 2014 | 32 | 0.490 |
Why?
|
| Internal Fixators | 1 | 2016 | 33 | 0.490 |
Why?
|
| Foreign Bodies | 1 | 2016 | 20 | 0.480 |
Why?
|
| Foot | 1 | 2016 | 40 | 0.480 |
Why?
|
| Synovitis, Pigmented Villonodular | 1 | 2016 | 2 | 0.480 |
Why?
|
| Radiotherapy | 1 | 2016 | 30 | 0.480 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 2016 | 32 | 0.480 |
Why?
|
| Ultrasonography, Interventional | 1 | 2016 | 64 | 0.470 |
Why?
|
| Acetabulum | 1 | 2016 | 161 | 0.450 |
Why?
|
| Osteosarcoma | 4 | 2021 | 36 | 0.440 |
Why?
|
| Radius | 1 | 2014 | 32 | 0.440 |
Why?
|
| Knee Prosthesis | 2 | 2008 | 200 | 0.430 |
Why?
|
| Tobramycin | 2 | 2005 | 8 | 0.420 |
Why?
|
| Survival Rate | 5 | 2021 | 318 | 0.410 |
Why?
|
| Arthralgia | 2 | 2011 | 100 | 0.390 |
Why?
|
| Biopsy | 5 | 2023 | 189 | 0.380 |
Why?
|
| Anti-Bacterial Agents | 3 | 2022 | 362 | 0.380 |
Why?
|
| Combined Modality Therapy | 3 | 2021 | 295 | 0.360 |
Why?
|
| Allografts | 4 | 2021 | 147 | 0.360 |
Why?
|
| Prognosis | 7 | 2023 | 730 | 0.350 |
Why?
|
| Histiocytosis, Sinus | 1 | 2011 | 4 | 0.340 |
Why?
|
| Proto-Oncogene Proteins c-akt | 3 | 2017 | 56 | 0.340 |
Why?
|
| Talus | 1 | 2011 | 13 | 0.340 |
Why?
|
| Edema | 1 | 2011 | 22 | 0.340 |
Why?
|
| Patellar Ligament | 1 | 2010 | 35 | 0.330 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2010 | 30 | 0.330 |
Why?
|
| Lung Neoplasms | 2 | 2015 | 539 | 0.320 |
Why?
|
| Follow-Up Studies | 6 | 2022 | 1412 | 0.310 |
Why?
|
| Prosthesis Failure | 3 | 2022 | 414 | 0.310 |
Why?
|
| Femur | 3 | 2022 | 298 | 0.300 |
Why?
|
| Debridement | 3 | 2016 | 66 | 0.300 |
Why?
|
| Reoperation | 6 | 2022 | 743 | 0.290 |
Why?
|
| Bone Plates | 1 | 2008 | 41 | 0.280 |
Why?
|
| Aged | 11 | 2021 | 7449 | 0.280 |
Why?
|
| Neoadjuvant Therapy | 5 | 2022 | 62 | 0.260 |
Why?
|
| Cisplatin | 3 | 2017 | 60 | 0.250 |
Why?
|
| Osteogenesis | 1 | 2007 | 99 | 0.250 |
Why?
|
| Aged, 80 and over | 6 | 2021 | 3729 | 0.250 |
Why?
|
| Osteomyelitis | 2 | 2005 | 17 | 0.240 |
Why?
|
| Curettage | 3 | 2022 | 9 | 0.230 |
Why?
|
| Arthroplasty, Replacement, Hip | 2 | 2022 | 686 | 0.220 |
Why?
|
| Humerus | 1 | 2005 | 89 | 0.220 |
Why?
|
| Knee Joint | 2 | 2008 | 572 | 0.220 |
Why?
|
| Joint Instability | 1 | 2008 | 312 | 0.220 |
Why?
|
| Infant | 3 | 2021 | 483 | 0.220 |
Why?
|
| Margins of Excision | 2 | 2022 | 29 | 0.210 |
Why?
|
| Lymphatic Metastasis | 2 | 2021 | 86 | 0.210 |
Why?
|
| Chondrosarcoma | 1 | 2023 | 38 | 0.200 |
Why?
|
| Spinal Neoplasms | 1 | 2023 | 34 | 0.200 |
Why?
|
| Orthopedic Procedures | 2 | 2004 | 225 | 0.200 |
Why?
|
| Embolization, Therapeutic | 1 | 2023 | 53 | 0.200 |
Why?
|
| Prostheses and Implants | 2 | 2015 | 132 | 0.190 |
Why?
|
| Kidney Neoplasms | 1 | 2023 | 75 | 0.190 |
Why?
|
| Neutrophils | 1 | 2023 | 89 | 0.190 |
Why?
|
| Injections | 2 | 2016 | 42 | 0.190 |
Why?
|
| Neoplasm Staging | 3 | 2022 | 356 | 0.190 |
Why?
|
| Plasma Gases | 1 | 2022 | 2 | 0.190 |
Why?
|
| Absorbable Implants | 1 | 2002 | 17 | 0.190 |
Why?
|
| Infant, Newborn | 2 | 2021 | 537 | 0.190 |
Why?
|
| Bone Cements | 3 | 2022 | 78 | 0.180 |
Why?
|
| Sarcoma, Synovial | 1 | 2022 | 11 | 0.180 |
Why?
|
| Vancomycin | 1 | 2002 | 51 | 0.180 |
Why?
|
| Transplantation, Homologous | 1 | 2002 | 198 | 0.170 |
Why?
|
| Orthopedics | 1 | 2002 | 77 | 0.170 |
Why?
|
| Lymphatic Vessels | 1 | 2021 | 8 | 0.170 |
Why?
|
| Myxosarcoma | 1 | 2020 | 3 | 0.170 |
Why?
|
| Hemipelvectomy | 1 | 2020 | 2 | 0.170 |
Why?
|
| Fibrosarcoma | 1 | 2020 | 9 | 0.170 |
Why?
|
| Pelvic Neoplasms | 1 | 2020 | 8 | 0.170 |
Why?
|
| Radiography | 3 | 2015 | 521 | 0.160 |
Why?
|
| Tomography, X-Ray Computed | 3 | 2015 | 577 | 0.160 |
Why?
|
| Immunohistochemistry | 2 | 2011 | 337 | 0.160 |
Why?
|
| Prosthesis-Related Infections | 1 | 2022 | 177 | 0.160 |
Why?
|
| Receptor, IGF Type 1 | 2 | 2017 | 21 | 0.160 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p27 | 2 | 2016 | 10 | 0.150 |
Why?
|
| Antineoplastic Agents | 3 | 2017 | 195 | 0.150 |
Why?
|
| Chemoradiotherapy | 1 | 2019 | 57 | 0.140 |
Why?
|
| Osteoarthritis | 1 | 2022 | 287 | 0.140 |
Why?
|
| Chemotherapy, Adjuvant | 2 | 2010 | 82 | 0.140 |
Why?
|
| Tumor Suppressor Protein p53 | 2 | 2016 | 85 | 0.140 |
Why?
|
| Hip Prosthesis | 1 | 2022 | 437 | 0.130 |
Why?
|
| Receptors, Somatomedin | 1 | 2017 | 5 | 0.130 |
Why?
|
| Protein Kinase Inhibitors | 2 | 2017 | 57 | 0.130 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2019 | 240 | 0.130 |
Why?
|
| Drug Resistance, Neoplasm | 2 | 2017 | 67 | 0.130 |
Why?
|
| Apoptosis | 4 | 2022 | 194 | 0.130 |
Why?
|
| Imidazoles | 1 | 2017 | 62 | 0.130 |
Why?
|
| Cohort Studies | 1 | 2021 | 1417 | 0.130 |
Why?
|
| Piperazines | 1 | 2017 | 82 | 0.130 |
Why?
|
| Ceramics | 1 | 2016 | 13 | 0.120 |
Why?
|
| Mechanistic Target of Rapamycin Complex 1 | 1 | 2016 | 9 | 0.120 |
Why?
|
| Cartilage, Articular | 2 | 2016 | 268 | 0.120 |
Why?
|
| Dogs | 2 | 2007 | 136 | 0.120 |
Why?
|
| Biocompatible Materials | 1 | 2016 | 69 | 0.120 |
Why?
|
| Synovectomy | 1 | 2016 | 5 | 0.120 |
Why?
|
| Child Development | 1 | 2016 | 67 | 0.120 |
Why?
|
| Prosthesis Design | 3 | 2022 | 384 | 0.120 |
Why?
|
| Femoral Neoplasms | 1 | 2015 | 4 | 0.110 |
Why?
|
| Disease Management | 1 | 2016 | 100 | 0.110 |
Why?
|
| Risk Factors | 2 | 2022 | 1971 | 0.110 |
Why?
|
| Prosthesis Implantation | 1 | 2015 | 25 | 0.110 |
Why?
|
| Supination | 1 | 2014 | 17 | 0.110 |
Why?
|
| Arthroplasty | 1 | 2016 | 107 | 0.110 |
Why?
|
| Lung | 1 | 2015 | 137 | 0.110 |
Why?
|
| Hand Strength | 1 | 2014 | 49 | 0.110 |
Why?
|
| Time Factors | 2 | 2022 | 1261 | 0.110 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2011 | 860 | 0.110 |
Why?
|
| Wrist Joint | 1 | 2014 | 56 | 0.110 |
Why?
|
| Drug Implants | 2 | 2005 | 8 | 0.110 |
Why?
|
| Protein Kinases | 1 | 2014 | 12 | 0.100 |
Why?
|
| Spinal Fusion | 1 | 2020 | 429 | 0.100 |
Why?
|
| Chondroma | 1 | 2012 | 4 | 0.090 |
Why?
|
| Fibrous Dysplasia of Bone | 1 | 2012 | 3 | 0.090 |
Why?
|
| Injections, Intralesional | 1 | 2012 | 28 | 0.090 |
Why?
|
| Range of Motion, Articular | 1 | 2014 | 564 | 0.090 |
Why?
|
| Positron Emission Tomography Computed Tomography | 2 | 2022 | 31 | 0.090 |
Why?
|
| Fluorodeoxyglucose F18 | 2 | 2022 | 35 | 0.090 |
Why?
|
| Recovery of Function | 1 | 2012 | 242 | 0.090 |
Why?
|
| Ankle | 1 | 2011 | 18 | 0.090 |
Why?
|
| Cell Line, Tumor | 3 | 2017 | 243 | 0.080 |
Why?
|
| Thoracoscopy | 1 | 2010 | 22 | 0.080 |
Why?
|
| Ilium | 1 | 2010 | 28 | 0.080 |
Why?
|
| Proportional Hazards Models | 2 | 2021 | 273 | 0.080 |
Why?
|
| Diagnosis, Differential | 1 | 2011 | 311 | 0.080 |
Why?
|
| Animals | 3 | 2007 | 3270 | 0.080 |
Why?
|
| Predictive Value of Tests | 1 | 2011 | 439 | 0.080 |
Why?
|
| Chicago | 1 | 2012 | 813 | 0.080 |
Why?
|
| Disease-Free Survival | 2 | 2021 | 171 | 0.070 |
Why?
|
| Survival Analysis | 1 | 2008 | 226 | 0.070 |
Why?
|
| Prospective Studies | 2 | 2023 | 1493 | 0.070 |
Why?
|
| Compressive Strength | 1 | 2007 | 13 | 0.070 |
Why?
|
| Elasticity | 1 | 2007 | 25 | 0.070 |
Why?
|
| Illinois | 1 | 2008 | 221 | 0.070 |
Why?
|
| Arthroscopy | 1 | 2011 | 552 | 0.060 |
Why?
|
| Heterocyclic Compounds, 3-Ring | 2 | 2017 | 13 | 0.060 |
Why?
|
| Phosphorylation | 2 | 2016 | 130 | 0.060 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2005 | 313 | 0.060 |
Why?
|
| Multivariate Analysis | 1 | 2005 | 286 | 0.050 |
Why?
|
| Cell Division | 2 | 2022 | 80 | 0.050 |
Why?
|
| Lower Extremity | 1 | 2023 | 33 | 0.050 |
Why?
|
| Surgical Flaps | 1 | 2023 | 50 | 0.050 |
Why?
|
| Age Factors | 1 | 2005 | 638 | 0.050 |
Why?
|
| Blood Loss, Surgical | 1 | 2023 | 53 | 0.050 |
Why?
|
| Lymphocyte Count | 1 | 2023 | 16 | 0.050 |
Why?
|
| Tumor Microenvironment | 1 | 2023 | 17 | 0.050 |
Why?
|
| Lymphocytes | 1 | 2023 | 51 | 0.050 |
Why?
|
| Preoperative Care | 1 | 2023 | 107 | 0.050 |
Why?
|
| Necrosis | 1 | 2022 | 24 | 0.050 |
Why?
|
| Replantation | 1 | 2022 | 9 | 0.050 |
Why?
|
| Drug Delivery Systems | 1 | 2002 | 25 | 0.050 |
Why?
|
| Bone Matrix | 1 | 2002 | 18 | 0.050 |
Why?
|
| Transplantation Immunology | 1 | 2002 | 2 | 0.050 |
Why?
|
| Forecasting | 1 | 2002 | 78 | 0.050 |
Why?
|
| Printing, Three-Dimensional | 1 | 2021 | 6 | 0.050 |
Why?
|
| Tissue and Organ Harvesting | 1 | 2002 | 14 | 0.050 |
Why?
|
| Time-to-Treatment | 1 | 2022 | 27 | 0.050 |
Why?
|
| Bone Regeneration | 1 | 2002 | 67 | 0.040 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2021 | 35 | 0.040 |
Why?
|
| Radiopharmaceuticals | 1 | 2022 | 48 | 0.040 |
Why?
|
| Positron-Emission Tomography | 1 | 2022 | 72 | 0.040 |
Why?
|
| Cartilage | 1 | 2002 | 70 | 0.040 |
Why?
|
| SEER Program | 1 | 2021 | 34 | 0.040 |
Why?
|
| Neoplasm Grading | 1 | 2021 | 50 | 0.040 |
Why?
|
| Neoplasm Invasiveness | 1 | 2021 | 88 | 0.040 |
Why?
|
| Chronic Disease | 1 | 2002 | 375 | 0.040 |
Why?
|
| Tendons | 1 | 2002 | 174 | 0.040 |
Why?
|
| Mutation | 1 | 2021 | 330 | 0.040 |
Why?
|
| Biomechanical Phenomena | 1 | 2002 | 536 | 0.040 |
Why?
|
| Mesna | 1 | 2019 | 3 | 0.040 |
Why?
|
| Ifosfamide | 1 | 2019 | 13 | 0.040 |
Why?
|
| Organ Sparing Treatments | 1 | 2019 | 11 | 0.040 |
Why?
|
| Leg | 1 | 2019 | 40 | 0.040 |
Why?
|
| Arm | 1 | 2019 | 68 | 0.040 |
Why?
|
| Doxorubicin | 1 | 2019 | 60 | 0.040 |
Why?
|
| Pyrazines | 1 | 2017 | 11 | 0.030 |
Why?
|
| Drug Synergism | 1 | 2017 | 38 | 0.030 |
Why?
|
| Receptor Cross-Talk | 1 | 2016 | 7 | 0.030 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2015 | 168 | 0.030 |
Why?
|
| Checkpoint Kinase 1 | 1 | 2014 | 7 | 0.030 |
Why?
|
| Cell Cycle Checkpoints | 1 | 2014 | 7 | 0.030 |
Why?
|
| Signal Transduction | 1 | 2016 | 387 | 0.030 |
Why?
|
| Gene Knockdown Techniques | 1 | 2014 | 40 | 0.030 |
Why?
|
| DNA Damage | 1 | 2014 | 25 | 0.030 |
Why?
|
| RNA Interference | 1 | 2014 | 36 | 0.030 |
Why?
|
| RNA, Small Interfering | 1 | 2014 | 76 | 0.030 |
Why?
|
| Enzyme Activation | 1 | 2014 | 109 | 0.030 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2014 | 111 | 0.020 |
Why?
|
| Culture Techniques | 1 | 1992 | 19 | 0.020 |
Why?
|
| Extracellular Matrix Proteins | 1 | 1992 | 40 | 0.020 |
Why?
|
| Proteoglycans | 1 | 1992 | 120 | 0.020 |
Why?
|
| Sepharose | 1 | 1992 | 4 | 0.010 |
Why?
|
| Hexuronic Acids | 1 | 1992 | 6 | 0.010 |
Why?
|
| Glucuronic Acid | 1 | 1992 | 6 | 0.010 |
Why?
|
| Alginates | 1 | 1992 | 7 | 0.010 |
Why?
|
| Gels | 1 | 1992 | 11 | 0.010 |
Why?
|
| Keratan Sulfate | 1 | 1992 | 15 | 0.010 |
Why?
|
| Lectins, C-Type | 1 | 1992 | 29 | 0.010 |
Why?
|
| Microspheres | 1 | 1992 | 24 | 0.010 |
Why?
|
| Cattle | 1 | 1992 | 110 | 0.010 |
Why?
|
| Extracellular Matrix | 1 | 1992 | 49 | 0.010 |
Why?
|
| Aggrecans | 1 | 1992 | 52 | 0.010 |
Why?
|
| Cells, Cultured | 1 | 1992 | 462 | 0.010 |
Why?
|